A phase II study (NCT01087151) demonstrated that in patients with chronic lymphocytic leukemia, the combination of rituximab and navitoclax exhibits higher effectiveness, prolonged progression-free survival, and better tolerance compared to rituximab monotherapy.

Authors

• Person: Not available Organization: Nature
  Cellular rejuvenation: molecular mechanisms and potential ... - Nature

Sources

• Cellular rejuvenation: molecular mechanisms and potential ... - Nature www.nature.com Nature via serper

Referenced by nodes (1)

• chronic lymphocytic leukemia concept